DRUG INDUCED HYPER PROLACTINEMIA: INTERESTING OBSERVATIONS.
-
Published:2022-09-15
Issue:
Volume:
Page:45-47
-
ISSN:
-
Container-title:PARIPEX INDIAN JOURNAL OF RESEARCH
-
language:en
-
Short-container-title:PIJR
Author:
Venkatanarasu Ashok1, Hanmayyagari Babul Reddy2, Guntaka Mounika3, Didwania Parikshit4
Affiliation:
1. Director Sanjeevani Thyroid, Sugar And Hormones Clinic,Hyderabad. 2. Associate professor, department of Endocrinology, Sapthagiri Institute of Medical sciences and Research Centre, Bengaluru, India 3. Associate professor, department of Biochemistry,Dr Patnam Mahender Reddy Institute of Medical Sciences,Chevella.Rangareddy,Telangana. 4. Medical Adviser,Mankind Pharma,Hyderabad
Abstract
Introduction: Drugs are a common cause of hyperprolactinemia. It is essential to differentiate this cause from other
pathological causes which avoids unnecessary investigations.Thorough history will help us in finding the responsible
drug and holding the same will be rewarding. Here we are reporting such cases of drug induced hyperprolactinemia.
Methods: It was a cross-sectional observational study. Subjects were recruited from our outpatient department.
Hyperprolactinemia was defined as blood prolactin levels >30 ng/mL in females and >24 ng/mL in males, regardless of
the presence of symptoms.Serum prolactin was repeated one week after holding the suspected drug(s).Drug induced
hyperprolactinemia defined,if holding of responsible drug made normalization of prolactin levels.Results: Total of 32
subjects were studied in this study with age of 35.5±10.8years.Predominantly female subjects were present with female
to male ratio 5.4. Basal prolactin was 132±68.7ng/mL and after holding the drug prolactin value was 16.9±8.2. Proton
pump inhibitors in combination with prokinetics were the leading cause (71.8%) and followed by multiple drug
combinations (15.6%), anti-psychiatric drugs (9.3%) and oral contraceptives (3.1%). The mean prolactin in the
combination of levosulpride was 176 ng/dl, whereas with domperidone it was 126 ng/dl & with oral contraceptives,
respiridone it was 134,151ng/dl respectively.Conclusion: Majority cases were clinically symptomatic. Among female
subjects commonest presentation was galactorrhea followed by irregular menses and breast heaviness and men
presented with erectile dysfunction.Contrary to common belief in our study PPI with prokinetic combination is the most
common offending agent than anti-psychotic agents. Levosulpride being the most potent drug in inducing hyper
prolactinemia than other agents, though the popular belief was with the Risperidone. As the utility of PPI prokinetic
combination is increasing, this might replace anti-psychotic agents as most potent & most common etiology for drug
induced hyper prolactinemia.
Publisher
World Wide Journals
Subject
Urban Studies,Multidisciplinary,General Veterinary,Animal Science and Zoology,Library and Information Sciences,Soil Science,General Veterinary,Agronomy and Crop Science,Animal Science and Zoology,Food Science,General Agricultural and Biological Sciences,Public Health, Environmental and Occupational Health,Health Policy,Industrial and Manufacturing Engineering,General Materials Science,Renewable Energy, Sustainability and the Environment,Forestry,General Veterinary,Agronomy and Crop Science,Animal Science and Zoology
Reference16 articles.
1. Gruen PH, Sachar EJ, Langer G, Altman N, Leifer M, Frantz A, et al. Prolactin responses to neuroleptics in normal and schizophrenic subjects. Archives of General Psychiatry. 1978 Jan 1; 35(1):108–16. 2. Inder WJ, Castle D: Antipsychotic-induced hyperprolactinaemia. Aust N Z J Psychiatry. 2011, 45:830-7. 3. Lopez-Vicchi F, De Winne C, Brie B, Sorianello E, Ladyman SR, Becu-Villalobos D. Metabolic functions of prolactin: Physiological and pathological aspects. J Neuroendocrinol. 2020;32:e12888. 4. Qiao Y, Yang F, Li C, Guo Q, Wen H, Zhu S, et al. Add-on effects of a low-dose aripiprazole in resolving hyperprolactinemia induced by risperidone or paliperidone. Psychiatry Res. 2016; 237:83–9. 5. Ryckmans V, Kahn JP, Modell S, Werner C, McQuade RD, Kerselaers W, et al. Switching to aripiprazole in outpatients with schizophrenia experiencing insufficient efficacy and/or safety/tolerability issues with risperidone: a randomized, multicentre, open-label study. Pharmacopsychiatry. 2009; 42:114–21.
|
|